Companies such as eMagin and Stemline Therapeutics have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should consider these financially stable, high-growth stocks. Analysing the most recent financial data, I’ve created a list of companies that compare favourably in all criteria, making them potentially good additions to your portfolio.
eMagin Corporation (AMEX:EMAN)
eMagin Corporation designs, develops, manufactures, and markets organic light emitting diode (OLED) on silicon micro displays; virtual imaging products that utilize OLED micro displays; and related products. Founded in 1993, and headed by CEO Andrew Sculley, the company provides employment to 92 people and has a market cap of USD $78.69M, putting it in the small-cap stocks category.
EMAN’s projected future profit growth is a robust 41.87%, with an underlying triple-digit growth from its revenues expected over the upcoming years. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. EMAN ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper.
Thinking of investing in EMAN? I recommend researching its fundamentals here.
Stemline Therapeutics, Inc. (NASDAQ:STML)
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. Started in 2003, and currently lead by Ivan Bergstein, the company now has 34 employees and has a market cap of USD $273.02M, putting it in the small-cap category.
STML’s projected future profit growth is a robust 25.69%, with an underlying triple-digit growth from its revenues expected over the upcoming years. It appears that STML’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. STML ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Thinking of investing in STML? Take a look at its other fundamentals here.
Ardelyx, Inc. (NASDAQ:ARDX)
Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Formed in 2007, and now led by CEO Michael Raab, the company provides employment to 93 people and with the company’s market capitalisation at USD $239.60M, we can put it in the small-cap category.
Want to know more about ARDX? Take a look at its other fundamentals here.
For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.